Related Experiment Video
Updated: Mar 7, 2026

Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring
Published on: June 23, 2015
Tolvaptan treatment for severe neonatal autosomal-dominant polycystic kidney disease
Rodney D Gilbert1,2, Hazel Evans3, Kazeem Olalekan4
1Regional Paediatric Nephro-Urology Unit, Southampton Children's Hospital, Tremona Road, Southampton, SO16 6YD, Hampshire, UK. Rodney.Gilbert@uhs.nhs.uk.
Background:
Severe neonatal autosomal-dominant polycystic kidney disease (ADPKD) is rare and easily confused with recessive PKD. Managing such infants is difficult and often unsuccessful.
Case Diagnosis/Treatment:
A female infant with massive renal enlargement, respiratory compromise and hyponatraemia was treated with the arginine vasopressin receptor 2 antagonist tolvaptan. This resolved hyponatraemia, and there was no further increase in renal size.
Conclusion:
Tolvaptan may be a useful treatment for severe neonatal PKD.
More Related Videos
08:46Implementing Patch Clamp and Live Fluorescence Microscopy to Monitor Functional Properties of Freshly Isolated PKD Epithelium
Published on: September 1, 2015
08:44Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema
Published on: September 1, 2016
Related Concept Videos
Renal Drug Excretion: Tubular Reabsorption
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
Renal Drug Excretion: Tubular Secretion
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Pharmacokinetics in Pediatric Patients: Drug Excretion
Continuous Renal Replacement Therapy